Takashima S, Doihara H, Yokoyama N, Tanada M, Soga H, Kurita A, Takiyama W, Saeki H, Moriwaki S
Dept. of Surgery, Shikoku Cancer Center Hospital.
Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 2):1600-3.
Recombinant interferon-beta (IFN-beta) shows a high anti-tumor effect on cancerous ascites, has little local irritative action and can safely be administered intraperitoneally. A randomized trial was conducted to evaluate the efficacy of intraperitoneal administration of IFN-beta for the purpose of preventing peritoneal metastasis of gastric cancer. The subjects selected were patients under 75 years of age who were macroscopically positive for serosal invasion and had undergone curative operation. Comparison was made by the envelope method between the cases given IFN-beta i.v. at 6 x 10(6) units continuously for 14 days from the day of operation and from 1 week after operation. MMC, 20 mg (i.v.) on the day of operation and 5-FU, 200 mg (p.o.) for 1 year from 2 weeks after operation were administered, respectively, in the two groups. The number of cases registered from March, 1987 to September, 1988 was 33, with 17 in the administration group and 16 in the control group. No difference was noted between the two groups in 3-year survival rate and disease free survival rate. As to the recurrence involving the peritoneum, however, there was a difference between the two groups, with 1 out of 6 cases in administration group and 3 out 4 cases in control group. Intraperitoneal chemotherapy can be an effective adjuvant therapy for gastric cancer, if cases are selected.
重组干扰素-β（IFN-β）对癌性腹水显示出高度抗肿瘤作用，局部刺激性小，可安全地腹腔内给药。进行了一项随机试验，以评估腹腔内给予IFN-β预防胃癌腹膜转移的疗效。所选受试者为75岁以下、肉眼可见浆膜侵犯且已接受根治性手术的患者。通过信封法对从手术当天起连续14天静脉注射6×10⁶单位IFN-β的病例与术后1周起开始注射的病例进行比较。两组分别在手术当天静脉注射丝裂霉素（MMC）20mg，并在术后2周起口服氟尿嘧啶（5-FU）200mg，持续1年。1987年3月至1988年9月登记的病例数为33例，给药组17例，对照组16例。两组的3年生存率和无病生存率无差异。然而，在腹膜复发方面，两组之间存在差异，给药组6例中有1例复发，对照组4例中有3例复发。如果病例选择得当，腹腔内化疗可以成为胃癌有效的辅助治疗方法。
